Nuwellis, Inc. (NUWE) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Nuwellis, Inc. is a medical technology company focused on the Aquadex System for ultrafiltration therapy to treat fluid overload in patients unresponsive to diuretics. The company is a non-accelerated filer and a smaller reporting company. As of June 30, 2024, the company had an accumulated deficit of $299.7 million and has raised substantial doubt about its ability to continue as a going concern without additional capital.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $2,194 | $2,075 | $4,051 | $3,901 |
| Gross Profit | $1,474 | $1,147 | $2,665 | $2,214 |
| Gross Margin | 67.2% | 55.3% | 65.8% | 56.8% |
| Net Loss | $(7,725) | $(4,845) | $(12,055) | $(11,330) |
| Loss Per Share (Basic/Diluted) | $(18.85) | $(127.65) | $(40.91) | $(323.15) |
| Cash and Equivalents | $1,023 | $8,896 (Q2 2023) | $1,023 (End of Period) | $8,896 (End of Period) |
| Operating Cash Flow (YTD) | $(5,616) | $(11,358) | $(5,616) | $(11,358) |
| Total Liabilities | $13,023 | $6,559 (Dec 2023) | $13,023 | $6,559 (Dec 2023) |
Note: Per share data reflects a 1-for-35 reverse stock split effective June 27, 2024. Significant non-cash financing expenses of $5.6 million were recorded in Q2 2024 related to warrant valuations.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.7% in Q2 2024 and 3.8% YTD compared to the prior year, driven by a 9-10% increase in circuit sales and higher console selling prices.
- Expense Reduction: Operating expenses decreased significantly. Selling, General, and Administrative (SG&A) expenses dropped 30.6% in Q2 and 22.8% YTD. R&D expenses fell 62.9% in Q2 and 35.5% YTD due to reduced consulting and compensation costs.
- Warrant Liability: Total liabilities increased from $6.6 million (Dec 2023) to $13.0 million (June 2024), primarily due to a $8.6 million warrant liability (up from $2.8 million). This includes a $5.6 million "Day 1" financing expense from an April 2024 offering where warrant valuation exceeded gross proceeds.
- Liquidity: Cash and cash equivalents declined from $3.8 million at year-end 2023 to $1.0 million at June 30, 2024.
Outlook, Risks, and Management Commentary
- Going Concern: Management states that existing capital resources are sufficient only through October 31, 2024. The company is actively seeking additional capital through debt or equity.
- Cost Cutting: The company has implemented measures to reduce its monthly cash burn rate by approximately 40%, including job eliminations, salary reductions for senior management, suspension of 401(k) matching, and travel reductions.
- Capital Raises:
- April 2024: Closed a public offering raising ~$2.7 million gross proceeds.
- July 2024 (Subsequent Event): Closed a registered direct offering and private placement raising ~$2.0 million gross proceeds.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's Minimum Bid Price and Stockholder's Equity requirements. A 1-for-35 reverse stock split was executed in June 2024. The company regained compliance with the bid price requirement but is awaiting a hearing panel decision regarding the Stockholder's Equity requirement.
- Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, citing two material weaknesses in financial reporting controls.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$3.0 million raised in July 2024 combined with existing cash to sustain operations beyond October 2024.
- Warrant Liability Impact: Assess the ongoing impact of warrant liability re-measurements on future net loss and the potential for further "Day 1" financing expenses in future capital raises.
- Nasdaq Listing Status: Monitor the outcome of the Nasdaq Hearings Panel regarding the Stockholder's Equity requirement to ensure continued listing.
- Revenue Concentration: Note that two customers represented 16% and 12% of Q2 2024 net sales; verify stability of these key accounts.
- Internal Controls: Review the remediation plan for the identified material weaknesses in financial reporting controls.